-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 T+yERtClUTmbSDk5gy35bZGUqOSNWZ1nndUnlXwRH0pLzNzOjOVUkSu3RsOiTpHY
 VlXq47LvBnylumlHHwYfVw==

<SEC-DOCUMENT>0001309014-08-000155.txt : 20080321
<SEC-HEADER>0001309014-08-000155.hdr.sgml : 20080321
<ACCEPTANCE-DATETIME>20080321100107
ACCESSION NUMBER:		0001309014-08-000155
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20080321
FILED AS OF DATE:		20080321
DATE AS OF CHANGE:		20080321

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KONINKLIJKE PHILIPS ELECTRONICS NV
		CENTRAL INDEX KEY:			0000313216
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTRONIC & OTHER ELECTRICAL EQUIPMENT (NO COMPUTER EQUIP) [3600]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-05146-01
		FILM NUMBER:		08704250

	BUSINESS ADDRESS:	
		STREET 1:		BREITNER CENTER
		STREET 2:		AMSTELPLEIN 2
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1096 BC
		BUSINESS PHONE:		31 20 59 77777

	MAIL ADDRESS:	
		STREET 1:		BREITNER CENTER
		STREET 2:		AMSTELPLEIN 2
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1096 BC

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIPS ELECTRONICS N V
		DATE OF NAME CHANGE:	19930727

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIPS NV
		DATE OF NAME CHANGE:	19910903
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>htm_2921.htm
<DESCRIPTION>LIVE FILING
<TEXT>
<!-- HTML Header Page -->
<HTML>
<HEAD>
<TITLE>
Koninklijke Philips Electronics N.V.&nbsp;-&nbsp;Form&nbsp;6-K
</TITLE>
</HEAD>
<!-- End HTML Header Page --><!-- Cover Page Header -->
<BODY bgcolor=white text=black>
<HR NOSHADE>
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<P align="center">
<FONT size="+1"><B>
UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B>
</P>

<P>
<CENTER>
<FONT SIZE="+2" FACE="Arial"><B>Form 6-K</B></FONT><BR>

</CENTER>
</P>

<P>
<CENTER>
<FONT size="+1">
REPORT OF FOREIGN PRIVATE ISSUER<BR>PURSUANT TO RULE 13a-16 OR 15d-16<BR>UNDER THE SECURITIES EXCHANGE ACT OF 1934
</FONT>
</CENTER>
</P>
<P>
<CENTER>
March 21, 2008
</CENTER>
</P>
<P>
<CENTER>

</CENTER>
</P>
<!-- End Cover Page Header -->
<!-- Cover Page Registrant -->
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="CENTER" WIDTH="100%" COLSPAN="5">
	<FONT SIZE="+2"><B>Koninklijke Philips Electronics N.V.</B></FONT><BR>
	<FONT SIZE="-7">&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;</FONT>
    </TD>
  </TR>
  <TR>
    <TD VALIGN="CENTER" ALIGN="CENTER" WIDTH="100%" COLSPAN="5">
	<FONT SIZE="-1">(Translation of registrant&#146;s name into English)</FONT>
    </TD>
  </TR>
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="CENTER" WIDTH="100%" COLSPAN="5">
	&nbsp;
    </TD>
  </TR>
<TR><TD VALIGN="BOTTOM" ALIGN="CENTER" WIDTH="100%" COLSPAN="5"><FONT FACE="Courier" SIZE="+0">The Netherlands</FONT><BR><FONT SIZE="-7">&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;</FONT></TD></TR><TR><TD VALIGN="CENTER" ALIGN="CENTER" WIDTH="100%" COLSPAN="5"><FONT SIZE="-1">(Jurisdiction of incorporation or organization)</FONT></TD></TR><TR><TD VALIGN="BOTTOM" ALIGN="CENTER" WIDTH="100%" COLSPAN="5">&nbsp;</TD></TR>
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="CENTER" WIDTH="100%" COLSPAN="5">
      <FONT FACE="Courier" SIZE="+0">Breitner Center, Amstelplein 2, 1096 BC Amsterdam, The Netherlands</FONT>
    </TD>
  </TR>
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="CENTER" WIDTH="100%" COLSPAN="5">
        <FONT SIZE="-7">&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;</FONT><BR>
	    <FONT SIZE="-1">(Address of principal executive office)</FONT>
    </TD>
  </TR>
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="CENTER" WIDTH="100%" COLSPAN="5">
	&nbsp;
    </TD>
  </TR>
</TABLE>
<!-- End Cover Page Registrant -->
<!-- Checkboxes Page -->
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="100%" COLSPAN="5">
	Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:&nbsp;&nbsp;[<FONT FACE="Courier">x</FONT>]&nbsp;Form 20-F&nbsp;&nbsp;&nbsp;&nbsp;[<FONT FACE="Courier">&nbsp;</FONT>]&nbsp;Form 40-F
    </TD>
  </TR>
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" COLSPAN="5" WIDTH="100%">
        &nbsp;
    </TD>
  </TR>

  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" COLSPAN="5" WIDTH="100%">
        Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;[<FONT FACE="Courier">&nbsp;</FONT>]
    </TD>
  </TR>

  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" COLSPAN="5" WIDTH="100%">
        &nbsp;
    </TD>
  </TR>

  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" COLSPAN="5" WIDTH="100%">
        Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;[<FONT FACE="Courier">&nbsp;</FONT>]
    </TD>
  </TR>

  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" COLSPAN="5" WIDTH="100%">
        &nbsp;
    </TD>
  </TR>

  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" COLSPAN="5" WIDTH="100%">
        Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:&nbsp;&nbsp;[<FONT FACE="Courier">&nbsp;</FONT>]&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;[<FONT FACE="Courier">x</FONT>]&nbsp;No
    </TD>
  </TR>

  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" COLSPAN="5" WIDTH="100%">
        &nbsp;
    </TD>
  </TR>
</TABLE>

<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="100%">
        If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):&nbsp;&nbsp;&nbsp;<FONT FACE="Courier"><U>&nbsp;n/a&nbsp;</U></FONT>
    </TD>
  </TR>
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="100%">
        &nbsp;
    </TD>
  </TR>
</TABLE>
<!-- End Checkboxes Page -->
<!-- HR Page Break  -->
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<!-- End HR Page Break --><!-- Report Page -->
<FONT SIZE="3">
<PRE>
This report comprises a copy of the following press releases:

- - &#8220;Philips completes acquisition of US-based VISICU&#8221;, dated February 21, 2008;

- - &#8220;Philips sells High Tech Plastics Optics in Suzhou, China to Triumph
Pan-Pacific Capital ltd. of Hong Kong&#8221;, dated February 22, 2008;

- - &#8220;Philips extends tender offer period to acquire Respironics&#8221;, dated February
25, 2008;

- - &#8220;Philips announces it will change the accounting treatment of remaining stake
in LG Display&#8221;, dated February 29, 2008;

- - &#8220;Philips announces filing of registration statement for benchmark USD Notes
Issuance&#8221;, dated March 4, 2008;

- - &#8220;Philips and Respironics announce satisfaction of antitrust approvals
condition to tender offer&#8221;, dated March 5, 2008;

- - &#8220;Mr. Louis Schweitzer to step down from Supervisory Board of Royal Philips
Electronics&#8221;, dated March 5, 2008;

- - &#8220;Philips successfully places USD 3.1 billion worth of Senior Notes&#8221;, dated
March 6, 2008;

- - &#8220;Philips announces conditions to tender offer to acquire Respironics have
met&#8221;, dated March 7, 2008;

- - &#8220;Philips further lowers its stake in LG Display to 13.2%&#8221;, dated March 12,
2008;

- - &#8220;Philips announces completion of tender offer to acquire Respironics&#8221;, dated
March 14, 2008;

- - &#8220;Philips announces completion of Respironics acquisition&#8221;, dated March 17,
2008;

- - &#8220;Philips and Ascent Profit sign EUR 25 million contract to deliver digital
radiography systems to China in 2008&#8221;, dated March 19, 2008;

- - &#8220;Philips completes cancellation of 59.9 million shares&#8221;, dated March 20, 2008.


</PRE>
</FONT>
<!-- End Report Page -->
<!-- Page Break  -->
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
 <!-- Page Break  -->
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<!-- End Page Break -->
<!-- Signatures Page Header -->
<FONT SIZE="+1">
<CENTER>
<B>SIGNATURES</B>
</CENTER>
</FONT>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="100%">
       &nbsp;
    </TD>
  </TR>
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="100%">
       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
    </TD>
  </TR>
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="100%">
       &nbsp;
    </TD>
  </TR>
</TABLE>
<!-- End Signatures Page Header -->
<!-- Signatures Page Details -->
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="40%">
       &nbsp;
    </TD>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="4%%">
       &nbsp;
    </TD>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="56%">
       Koninklijke Philips Electronics N.V.
    </TD>
  </TR>

  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="40%">
       &nbsp;
    </TD>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="4%%">
       &nbsp;
    </TD>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="56%">
       &nbsp;
    </TD>
  </TR>

  <TR>
    <TD VALIGN="TOP" ALIGN="LEFT" WIDTH="40%">
       Date: March 21, 2008
    </TD>
    <TD VALIGN="TOP" ALIGN="LEFT" WIDTH="4%%">
       By:
    </TD>
    <TD VALIGN="TOP" ALIGN="LEFT" WIDTH="56%">
       /s/ E.P. Coutinho<BR><HR WIDTH="30%" NOSHADE>
    </TD>
  </TR>

  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="40%">
       &nbsp;
    </TD>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="4%%">
       Name:&nbsp;
    </TD>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="56%">
        E.P. Coutinho
    </TD>
  </TR>

  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="40%">
       &nbsp;
    </TD>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="4%%">
       Title:
    </TD>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="56%">
       General Secretary
    </TD>
  </TR>
  <TR>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="40%">
       &nbsp;
    </TD>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="4%%">
       &nbsp;
    </TD>
    <TD VALIGN="BOTTOM" ALIGN="LEFT" WIDTH="56%">
       &nbsp;
    </TD>
  </TR>
</TABLE>
<!-- End Signatures Page Details -->
<!-- HR Page Break  -->
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<!-- End HR Page Break --><!-- Exhibit Index Header Page -->
<CENTER>
<FONT SIZE="+1"><B>
EXHIBIT&nbsp;INDEX
</B></FONT>
</CENTER>
<BR>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="60%">
  <TR VALIGN="BOTTOM">
    <TD NOWRAP ALIGN="LEFT" WIDTH="8%">
      <FONT SIZE="-1"><B>Exhibit No.</B></FONT>
    </TD>
    <TD WIDTH="15%">
      &nbsp;
    </TD>
    <TD NOWRAP ALIGN="LEFT" WIDTH="77%">
      <FONT SIZE="-1"><B>Description</B></FONT>
    </TD>
  </TR>
  <TR VALIGN="BOTTOM">
    <TD NOWRAP ALIGN="CENTER" WIDTH="8%">
      <HR SIZE="1" NOSHADE>
    </TD>
    <TD WIDTH="15%">
      &nbsp;
    </TD>
    <TD NOWRAP ALIGN="CENTER" WIDTH="77%">
      <HR ALIGN="LEFT" SIZE="1" WIDTH="88%" NOSHADE>
    </TD>
  </TR>
<!-- Exhibit Index Header Page -->
<!-- Exhibit Index Item -->
  <TR VALIGN="BOTTOM">
    <TD VALIGN="TOP" WIDTH="8%" nowrap>
      <FONT SIZE="-1">99.01<FONT>
    </TD>
    <TD WIDTH="15%">
       &nbsp;
    </TD>
    <TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
      <FONT SIZE="2">Press release</FONT>
    </TD>
  </TR>
<!-- End Exhibit Index Item -->
<!-- Exhibit Index Item -->
  <TR VALIGN="BOTTOM">
    <TD VALIGN="TOP" WIDTH="8%" nowrap>
      <FONT SIZE="-1">99.02<FONT>
    </TD>
    <TD WIDTH="15%">
       &nbsp;
    </TD>
    <TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
      <FONT SIZE="2">Press release</FONT>
    </TD>
  </TR>
<!-- End Exhibit Index Item -->
<!-- Exhibit Index Item -->
  <TR VALIGN="BOTTOM">
    <TD VALIGN="TOP" WIDTH="8%" nowrap>
      <FONT SIZE="-1">99.03<FONT>
    </TD>
    <TD WIDTH="15%">
       &nbsp;
    </TD>
    <TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
      <FONT SIZE="2">Press release</FONT>
    </TD>
  </TR>
<!-- End Exhibit Index Item -->
<!-- Exhibit Index Item -->
  <TR VALIGN="BOTTOM">
    <TD VALIGN="TOP" WIDTH="8%" nowrap>
      <FONT SIZE="-1">99.04<FONT>
    </TD>
    <TD WIDTH="15%">
       &nbsp;
    </TD>
    <TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
      <FONT SIZE="2">Press release</FONT>
    </TD>
  </TR>
<!-- End Exhibit Index Item -->
<!-- Exhibit Index Item -->
  <TR VALIGN="BOTTOM">
    <TD VALIGN="TOP" WIDTH="8%" nowrap>
      <FONT SIZE="-1">99.05<FONT>
    </TD>
    <TD WIDTH="15%">
       &nbsp;
    </TD>
    <TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
      <FONT SIZE="2">Press release</FONT>
    </TD>
  </TR>
<!-- End Exhibit Index Item -->
<!-- Exhibit Index Item -->
  <TR VALIGN="BOTTOM">
    <TD VALIGN="TOP" WIDTH="8%" nowrap>
      <FONT SIZE="-1">99.06<FONT>
    </TD>
    <TD WIDTH="15%">
       &nbsp;
    </TD>
    <TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
      <FONT SIZE="2">Press release</FONT>
    </TD>
  </TR>
<!-- End Exhibit Index Item -->
<!-- Exhibit Index Item -->
  <TR VALIGN="BOTTOM">
    <TD VALIGN="TOP" WIDTH="8%" nowrap>
      <FONT SIZE="-1">99.07<FONT>
    </TD>
    <TD WIDTH="15%">
       &nbsp;
    </TD>
    <TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
      <FONT SIZE="2">Press release</FONT>
    </TD>
  </TR>
<!-- End Exhibit Index Item -->
<!-- Exhibit Index Item -->
  <TR VALIGN="BOTTOM">
    <TD VALIGN="TOP" WIDTH="8%" nowrap>
      <FONT SIZE="-1">99.08<FONT>
    </TD>
    <TD WIDTH="15%">
       &nbsp;
    </TD>
    <TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
      <FONT SIZE="2">Press release</FONT>
    </TD>
  </TR>
<!-- End Exhibit Index Item -->
<!-- Exhibit Index Item -->
  <TR VALIGN="BOTTOM">
    <TD VALIGN="TOP" WIDTH="8%" nowrap>
      <FONT SIZE="-1">99.09<FONT>
    </TD>
    <TD WIDTH="15%">
       &nbsp;
    </TD>
    <TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
      <FONT SIZE="2">Press release</FONT>
    </TD>
  </TR>
<!-- End Exhibit Index Item -->
<!-- Exhibit Index Item -->
  <TR VALIGN="BOTTOM">
    <TD VALIGN="TOP" WIDTH="8%" nowrap>
      <FONT SIZE="-1">99.10<FONT>
    </TD>
    <TD WIDTH="15%">
       &nbsp;
    </TD>
    <TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
      <FONT SIZE="2">Press release</FONT>
    </TD>
  </TR>
<!-- End Exhibit Index Item -->
<!-- Exhibit Index Item -->
  <TR VALIGN="BOTTOM">
    <TD VALIGN="TOP" WIDTH="8%" nowrap>
      <FONT SIZE="-1">99.11<FONT>
    </TD>
    <TD WIDTH="15%">
       &nbsp;
    </TD>
    <TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
      <FONT SIZE="2">Press release</FONT>
    </TD>
  </TR>
<!-- End Exhibit Index Item -->
<!-- Exhibit Index Item -->
  <TR VALIGN="BOTTOM">
    <TD VALIGN="TOP" WIDTH="8%" nowrap>
      <FONT SIZE="-1">99.12<FONT>
    </TD>
    <TD WIDTH="15%">
       &nbsp;
    </TD>
    <TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
      <FONT SIZE="2">Press release</FONT>
    </TD>
  </TR>
<!-- End Exhibit Index Item -->
<!-- Exhibit Index Item -->
  <TR VALIGN="BOTTOM">
    <TD VALIGN="TOP" WIDTH="8%" nowrap>
      <FONT SIZE="-1">99.13<FONT>
    </TD>
    <TD WIDTH="15%">
       &nbsp;
    </TD>
    <TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
      <FONT SIZE="2">Press release</FONT>
    </TD>
  </TR>
<!-- End Exhibit Index Item -->
<!-- Exhibit Index Item -->
  <TR VALIGN="BOTTOM">
    <TD VALIGN="TOP" WIDTH="8%" nowrap>
      <FONT SIZE="-1">99.14<FONT>
    </TD>
    <TD WIDTH="15%">
       &nbsp;
    </TD>
    <TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
      <FONT SIZE="2">Press release</FONT>
    </TD>
  </TR>
<!-- End Exhibit Index Item -->
<!-- ExhibitIndexFooter -->
  <TR VALIGN="BOTTOM">
    <TD VALIGN="TOP" WIDTH="8%" nowrap>
      &nbsp;
    </TD>
    <TD WIDTH="15%">
       &nbsp;
    </TD>
    <TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
      &nbsp;
    </TD>
  </TR>
</TABLE>
<!-- End ExhibitIndexFooter -->
<!-- HR Page Break  -->
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<!-- End HR Page Break --><!-- HTML Footer Page -->
</BODY>
</HTML>
<!-- End HTML Footer Page -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.01
<SEQUENCE>2
<FILENAME>exhibit1.htm
<DESCRIPTION>EX-99.01
<TEXT>
<!-- ExhibitContentHeader Page -->
<HTML>
<HEAD>
<TITLE>
Exhibit&nbsp;&nbsp;EX-99.01
</TITLE>
</HEAD>
<!-- End HTML Header Page -->
<!-- ExhibitContentPage -->

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt">February&nbsp;21, 2008
</FONT>

<P align="left" style="font-size: 12pt">PHILIPS COMPLETES ACQUISITION OF US-BASED VISICU


<P align="left" style="font-size: 12pt">Amsterdam, The Netherlands &#150; Royal Philips Electronics (AEX:PHI, NYSE:PHG) (&#147;Philips&#148;) and VISICU
Inc. (NASDAQ: EICU) today announced that Philips has completed its acquisition of VISICU through
the merger of its indirect wholly-owned subsidiary with and into VISICU. As a result of the merger,
VISICU has become an indirect wholly-owned subsidiary of Philips. As of the first quarter of 2008,
VISICU&#146;s financial results will be accounted for in the financial results of the Patient Monitoring
business unit within Philips Healthcare.


<P align="left" style="font-size: 12pt">VISICU has requested that the NASDAQ file a Form&nbsp;25 with the United States Securities and Exchange
Commission causing the delisting of VISICU&#146;s common stock from the NASDAQ and the deregistration of
its common stock under the United States federal securities laws.


<P align="left" style="font-size: 12pt">To view Philips&#146; December&nbsp;18, 2007 press release, announcing Philips&#146; intention to acquire VISICU,
please click <B>here</B>.


<P align="left" style="font-size: 12pt">For further information please contact:
<BR>
Jayson Otke
<BR>
Philips Corporate Communications
<BR>
Tel: &#043;31 20 59 77215
<BR>
Email: jayson.otke@philips.com


<P align="left" style="font-size: 12pt">Andre Manning
<BR>
Philips Healthcare
<BR>
Tel: &#043;1 646 508 4545
<BR>
Email: <U>andre.manning@philips.com</U>


<P align="left" style="font-size: 12pt">Robert Pepper
<BR>
VISICU, Inc.
<BR>
Tel: &#043;1 410 246 5364
<BR>
Email: rpepper@visicu.com


<P align="left" style="font-size: 12pt">About Royal Philips Electronics
<BR>
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in
healthcare, lighting and consumer lifestyle, delivering people-centric, innovative products,
services and solutions through the brand promise of &#147;sense and simplicity&#148;. Headquartered in the
Netherlands, Philips employs approximately 123,800 employees in more than 60 countries worldwide.
With sales of EUR 27&nbsp;billion in 2007, the company is a market leader in medical diagnostic imaging
and patient monitoring systems, energy efficient lighting solutions, as well as lifestyle solutions
for personal wellbeing. News from Philips is located at www.philips.com/newscenter.


<P align="left" style="font-size: 12pt">About Visicu
<BR>
VISICU, Inc. (NASDAQ: EICU) is a healthcare information technology and clinical solutions company
focused on transforming the delivery of critical care through its eICU&#174; Program. Through remote
monitoring technology and clinical intelligence, experienced critical care resources are leveraged
to provide coverage and early intervention for safer, more effective patient care. Currently more
than 180 hospitals serving over 250,000 patients annually have partnered with VISICU to implement
eICU programs. More information is available at www.VISICU.com. VISICU&#174; and eICU&#174; are registered
trademarks of VISICU, Inc. All rights reserved. All other brand names, product names, company
names, trademarks and service marks are the property of their respective owners. visicu-g


<P align="left" style="font-size: 12pt">Forward-looking statements
<BR>
This release may contain certain forward-looking statements with respect to the financial
condition, results of operations and business of Philips and certain of the plans and objectives of
Philips with respect to these items. By their nature, forward-looking statements involve risk and
uncertainty because they relate to events and depend on circumstances that will occur in the future
and there are many factors that could cause actual results and developments to differ materially
from those expressed or implied by these forward-looking statements. Any forward-looking statements
in this announcement are based upon information known to Philips on the date of this announcement.
Philips undertakes no obligation to publicly update or revise any forward-looking statement,
whether as a result of new information, future events or otherwise.



<P align="center" style="font-size: 10pt; display: none">


<!-- v.060107 -->
</BODY>

<!-- End ExhibitContentPage -->
<!-- ExhibitContentFooter Page -->
</HTML>
<!-- ExhibitContentFooter Page -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.02
<SEQUENCE>3
<FILENAME>exhibit2.htm
<DESCRIPTION>EX-99.02
<TEXT>
<!-- ExhibitContentHeader Page -->
<HTML>
<HEAD>
<TITLE>
Exhibit&nbsp;&nbsp;EX-99.02
</TITLE>
</HEAD>
<!-- End HTML Header Page -->
<!-- ExhibitContentPage -->

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt">February&nbsp;22, 2008
</FONT>

<P align="left" style="font-size: 12pt">PHILIPS SELLS HIGH TECH PLASTICS OPTICS IN SUZHOU, CHINA TO TRIUMPH PAN-PACIFIC CAPITAL LTD. OF
HONG KONG


<P align="left" style="font-size: 12pt">Amsterdam, the Netherlands &#151; Royal Philips Electronics (NYSE: PHG, AEX: PHI) today announced it has
sold a 90% stake in its High Tech Plastics (HTP)&nbsp;Optics business in Suzhou, China to Triumph
Pan-Pacific Capital Limited of Hong Kong for an undisclosed amount. Philips expects to record a
loss of approximately EUR 12&nbsp;million in its first quarter results as a result of the sale of these
activities. HTP Optics Suzhou manufactures plastic, high-precision lenses used in camera phones,
compact disc and DVD readers, and in scanners. The company employs approximately 300 people,
primarily in Suzhou, China.


<P align="left" style="font-size: 12pt">The sale of the majority stake in HTP Optics Suzhou represents another step Philips is taking to
focus on its Healthcare, Lighting and Consumer Lifestyle activities supported by the strength of
the company&#146;s brand. HTP Optics Suzhou was part of Philips&#146; Corporate Investments portfolio within
Philips&#146; Innovation &#038; Emerging Businesses sector.


<P align="left" style="font-size: 12pt">For further information please contact:
<BR>
Jayson Otke
<BR>
Philips Corporate Communications
<BR>
Tel: &#043;31 20 59 77215
<BR>
Email: jayson.otke@philips.com


<P align="left" style="font-size: 12pt">About Royal Philips Electronics
<BR>
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in
healthcare, lighting and consumer lifestyle, delivering people-centric, innovative products,
services and solutions through the brand promise of &#147;sense and simplicity&#148;. Headquartered in the
Netherlands, Philips employs approximately 123,800 employees in more than 60 countries worldwide.
With sales of EUR 27&nbsp;billion in 2007, the company is a market leader in medical diagnostic imaging
and patient monitoring systems, energy efficient lighting solutions, as well as lifestyle solutions
for personal wellbeing. News from Philips is located at www.philips.com/newscenter.


<P align="left" style="font-size: 12pt">Forward-looking statements
<BR>
This release may contain certain forward-looking statements with respect to the financial
condition, results of operations and business of Philips and certain of the plans and objectives of
Philips with respect to these items. By their nature, forward-looking statements involve risk and
uncertainty because they relate to events and depend on circumstances that will occur in the future
and there are many factors that could cause actual results and developments to differ materially
from those expressed or implied by these forward-looking statements.



<P align="center" style="font-size: 10pt; display: none">


<!-- v.060107 -->
</BODY>

<!-- End ExhibitContentPage -->
<!-- ExhibitContentFooter Page -->
</HTML>
<!-- ExhibitContentFooter Page -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.03
<SEQUENCE>4
<FILENAME>exhibit3.htm
<DESCRIPTION>EX-99.03
<TEXT>
<!-- ExhibitContentHeader Page -->
<HTML>
<HEAD>
<TITLE>
Exhibit&nbsp;&nbsp;EX-99.03
</TITLE>
</HEAD>
<!-- End HTML Header Page -->
<!-- ExhibitContentPage -->

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt">February&nbsp;25, 2008
</FONT>

<P align="left" style="font-size: 12pt">PHILIPS EXTENDS TENDER OFFER PERIOD TO ACQUIRE RESPIRONICS


<P align="left" style="font-size: 12pt">Amsterdam, The Netherlands and Murrysville, Pennsylvania &#150; Royal Philips Electronics (NYSE:PHG,
AEX:PHI) (&#147;Philips&#148;) and Respironics, Inc. (Nasdaq:RESP) (&#147;Respironics&#148;) today announced that
Philips&#146; indirect wholly owned subsidiary Moonlight Merger Sub, Inc. (&#147;Philips Merger Sub&#148;) is
extending the expiration date for its previously announced tender offer until 5:00 p.m., New York
City time, on March&nbsp;6, 2008 for all outstanding shares of common stock of Respironics for $66.00
per Respironics share, without interest and subject to any applicable withholding of taxes.


<P align="left" style="font-size: 12pt">On January&nbsp;3, 2008, Philips Merger Sub commenced the tender offer for the Respironics shares in
accordance with the Agreement and Plan of Merger, dated as of December&nbsp;20, 2007, by and among
Respironics, Philips Holding USA Inc. and Philips Merger Sub, which was amended to provide for the
above described extension. The offer is being extended because, as of 12:00 midnight, New York City
time, on February&nbsp;22, 2008, not all conditions to the offer had been satisfied or waived by Philips
Merger Sub, including the approval under Council Regulation (EC)&nbsp;No.&nbsp;139/2004 of the European
Community, as amended (the &#147;EC Merger Regulation&#148;). The formal notification and application for
approval of the offer and the merger under the EC Merger Regulation was filed on January&nbsp;30, 2008
and the 25 working day review period under the EC Merger Regulation will expire on March&nbsp;5, 2008.
As of 12:00 midnight, New York City time, on February&nbsp;22, 2008, Philips Merger Sub had received a
preliminary number of tenders representing approximately 63.7&nbsp;million of the outstanding
Respironics shares, which represented approximately 82&nbsp;percent of the outstanding Respironics
shares (on a fully diluted basis).


<P align="left" style="font-size: 12pt">Investors and stockholders of Respironics are urged to read the Tender Offer Statement on Schedule
TO (containing the offer to purchase, a letter of transmittal and related materials) relating to
the tender offer that has been filed with the Securities and Exchange Commission (the &#147;SEC&#148;)
because it contains important information, including the various terms of, and conditions to, the
tender offer. Investors and stockholders of Respironics may obtain these and other documents
regarding the tender offer, the merger and the related transactions filed by Philips Merger Sub and
Respironics for free from the SEC&#146;s website at www.sec.gov.


<P align="left" style="font-size: 12pt">Georgeson Inc. is the Information Agent for the tender offer and any questions or requests for
assistance or free copies of the offer to purchase and the letter of transmittal may be directed to
it at 199 Water Street, 26th Floor, New York, NY 10038 or by telephone toll-free at (800)&nbsp;491-3017
or at (212)&nbsp;440-9800 (bankers and brokers only). Deutsche Bank is the Dealer Manager for the tender
offer and can be reached at 60 Wall Street, New York, NY 10005 or by telephone toll-free at (877)
221-7676.


<P align="left" style="font-size: 12pt">This release is for informational purposes only and is not an offer to purchase or a solicitation
of an offer to sell Respironics shares, nor is it an offer to purchase or a solicitation of an
offer to sell any securities. The tender offer is made solely by means of the offer to purchase.


<P align="left" style="font-size: 12pt">For further information, please contact:
<BR>
Arent Jan Hesselink
<BR>
Philips Corporate Communications
<BR>
Tel: &#043;31 20 59 77415
<BR>
Email: arentjan.hesselink@philips.com


<P align="left" style="font-size: 12pt">Andre Manning
<BR>
Philips Healthcare
<BR>
Tel: &#043;1 646 508 4545
<BR>
Email: andre.manning@philips.com


<P align="left" style="font-size: 12pt">Dan Bevevino
<BR>
Vice President &#038; CFO, Respironics
<BR>
Tel: &#043;1 724 387 5235


<P align="left" style="font-size: 12pt">Maryellen Bizzack
<BR>
Director, Marketing &#038; Communications, Respironics
<BR>
Tel: &#043;1 724 387 5006


<P align="left" style="font-size: 12pt">About Royal Philips Electronics
<BR>
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in
healthcare, lighting and consumer lifestyle, delivering people-centric, innovative products,
services and solutions through the brand promise of &#147;sense and simplicity&#148;. Headquartered in the
Netherlands, Philips employs approximately 123,800 employees in more than 60 countries worldwide.
With sales of EUR 27&nbsp;billion in 2007, the company is a market leader in medical diagnostic imaging
and patient monitoring systems, energy efficient lighting solutions, as well as lifestyle solutions
for personal wellbeing. News from Philips is located at www.philips.com/newscenter.


<P align="left" style="font-size: 12pt">About Respironics
<BR>
Respironics is a leading developer, manufacturer and distributor of innovative products and
programs that serve the global sleep and respiratory markets. Focusing on emerging market needs,
the Company is committed to providing valued solutions to help improve outcomes for patients,
clinicians and healthcare providers. Respironics markets its products in 141 countries and employs
over 5,300 associates worldwide. Further information can be found on the Company&#146;s Web site:
www.respironics.com.


<P align="left" style="font-size: 12pt">Forward-looking statements
<BR>
This release may contain certain forward-looking statements with respect to the financial
condition, results of operations and business of Philips and certain of the plans and objectives of
Philips with respect to these items, including without limitation completion of the tender offer
and merger and any expected benefits of the merger. Completion of the tender offer and merger are
subject to conditions, including satisfaction of a minimum tender condition and the need for
regulatory approvals, and there can be no assurance that those conditions can be satisfied or that
the transactions described in this press release will completed. By their nature, forward-looking
statements involve risk and uncertainty because they relate to events and depend on circumstances
that will occur in the future and there are many factors that could cause actual results and
developments to differ materially from those expressed or implied by these forward-looking
statements. Any forward-looking statements in this announcement are based upon information known to
Philips on the date of this announcement. Philips undertakes no obligation to publicly update or
revise any forward-looking statement, whether as a result of new information, future events or
otherwise.



<P align="center" style="font-size: 10pt; display: none">


<!-- v.060107 -->
</BODY>

<!-- End ExhibitContentPage -->
<!-- ExhibitContentFooter Page -->
</HTML>
<!-- ExhibitContentFooter Page -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.04
<SEQUENCE>5
<FILENAME>exhibit4.htm
<DESCRIPTION>EX-99.04
<TEXT>
<!-- ExhibitContentHeader Page -->
<HTML>
<HEAD>
<TITLE>
Exhibit&nbsp;&nbsp;EX-99.04
</TITLE>
</HEAD>
<!-- End HTML Header Page -->
<!-- ExhibitContentPage -->

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt">February&nbsp;29, 2008
</FONT>

<P align="left" style="font-size: 12pt">PHILIPS ANNOUNCES IT WILL CHANGE THE ACCOUNTING TREATMENT OF REMAINING STAKE IN LG DISPLAY


<P align="left" style="font-size: 12pt">Amsterdam, The Netherlands &#150; Royal Philips Electronics (NYSE:PHG, AEX:PHI) today announced that
effective March&nbsp;1, 2008, it will abandon equity accounting for its current shareholding in LG
Display Co., Ltd. (NYSE: LPL, KRX: 034220), formerly known as LG.Philips LCD Co., Ltd. Instead,
Philips will apply fair-value accounting for this participation effective as of the same date. This
change follows the reduction of Philips&#146; stake in LG Display to 19.9% in October&nbsp;2007, and the
stepping down of Mr.&nbsp;Rudy Provoost, Executive Vice President and member of the Philips Board of
Management, as Chairman of the Board of Directors of LG Display, effective today.


<P align="left" style="font-size: 12pt">As per March&nbsp;1, 2008, the difference between the book value of Philips&#146; interest in LG Display
(approximately EUR 1,635&nbsp;million) and the then-current fair value of this stake (which stands at
EUR 2,300&nbsp;million as of today) will be added to accumulated other comprehensive income as part of
Philips&#146; group equity.


<P align="left" style="font-size: 12pt">LG Display shareholders today approved the appointment of Mr.&nbsp;Paul Verhagen, Executive Vice
President and Chief Financial Officer of Philips Consumer Lifestyle, as a member of the LG Display
Board of Directors.


<P align="left" style="font-size: 12pt">For more information, please contact:
<BR>
Arent Jan Hesselink
<BR>
Philips Corporate Communications
<BR>
Tel: &#043;31 20 59 77415
<BR>
Email: arentjan.hesselink@philips.com


<P align="left" style="font-size: 12pt">About Royal Philips Electronics
<BR>
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in
healthcare, lighting and consumer lifestyle, delivering people-centric, innovative products,
services and solutions through the brand promise of &#147;sense and simplicity&#148;. Headquartered in the
Netherlands, Philips employs approximately 123,800 employees in more than 60 countries worldwide.
With sales of EUR 27&nbsp;billion in 2007, the company is a market leader in medical diagnostic imaging
and patient monitoring systems, energy efficient lighting solutions, as well as lifestyle solutions
for personal wellbeing. News from Philips is located at www.philips.com/newscenter.



<P align="center" style="font-size: 10pt; display: none">


<!-- v.060107 -->
</BODY>

<!-- End ExhibitContentPage -->
<!-- ExhibitContentFooter Page -->
</HTML>
<!-- ExhibitContentFooter Page -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.05
<SEQUENCE>6
<FILENAME>exhibit5.htm
<DESCRIPTION>EX-99.05
<TEXT>
<!-- ExhibitContentHeader Page -->
<HTML>
<HEAD>
<TITLE>
Exhibit&nbsp;&nbsp;EX-99.05
</TITLE>
</HEAD>
<!-- End HTML Header Page -->
<!-- ExhibitContentPage -->

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt">March&nbsp;04, 2008
</FONT>

<P align="left" style="font-size: 12pt">PHILIPS ANNOUNCES FILING OF REGISTRATION STATEMENT FOR BENCHMARK USD NOTES ISSUANCE


<P align="left" style="font-size: 12pt">Amsterdam, The Netherlands <B>&#150; </B>Royal Philips Electronics (NYSE:PHG, AEX:PHI) today announced that it
has filed a registration statement with the U.S. Securities and Exchange Commission in connection
with its intention to launch a USD benchmark issue (&#147;the Notes&#147;) to refinance the EUR 1.7&nbsp;billion
worth of Philips notes that mature during the course of 2008 and for general corporate purposes.
Certain variables of this intended issuance such as total size and maturity of the notes are still
to be determined.


<P align="left" style="font-size: 12pt">The notes to be issued are expected to be rated A3 stable outlook by Moody&#146;s and A- stable outlook
by Standard &#038; Poor&#146;s, which are the ratings of Philips&#146; existing long-term debt.


<P align="left" style="font-size: 12pt">For more information, please contact:
<BR>
Arent Jan Hesselink
<BR>
Philips Corporate Communications
<BR>
Tel: &#043;31 20 59 77415
<BR>
Email: arentjan.hesselink@philips.com


<P align="left" style="font-size: 12pt">About Royal Philips Electronics
<BR>
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in
healthcare, lighting and consumer lifestyle, delivering people-centric, innovative products,
services and solutions through the brand promise of &#147;sense and simplicity&#148;. Headquartered in the
Netherlands, Philips employs approximately 123,800 employees in more than 60 countries worldwide.
With sales of EUR 27&nbsp;billion in 2007, the company is a market leader in medical diagnostic imaging
and patient monitoring systems, energy efficient lighting solutions, as well as lifestyle solutions
for personal wellbeing. News from Philips is located at www.philips.com/newscenter.


<P align="left" style="font-size: 12pt">Securities Ratings: The securities ratings referred to above in this release are not a
recommendation to buy, sell or hold securities and the ratings are subject to revision or
withdrawal at anytime by the assigning rating agencies. Each rating should be evaluated
independently of any other rating.


<P align="left" style="font-size: 12pt">This release does not constitute an offer of any securities for sale. Any offer or sale of
securities shall only be made in accordance with the requirements of the US Securities Act of 1933.
<BR>
Any offer and sale of any securities outside the United States will be made in accordance with
local laws and regulations. In addition, any offer of securities in the member states of the
European Economic Area shall be made to qualified investors only within the meaning of article 3 of
Directive 2003/71/EC (the Prospectus Directive).


<P align="left" style="font-size: 12pt">When available, a copy of the written prospectus is available from J.P. Morgan Securities Inc, 270
Park Avenue New York, NY 10017, Attn: Nicholas Balzano (&#043;212-834-4533), or Citigroup Global
Markets, 33 Canada Square Canary Wharf London E14 5LB, Attn: Tomas Lundquist (&#043;44 20 7986 8962).



<P align="center" style="font-size: 10pt; display: none">


<!-- v.060107 -->
</BODY>

<!-- End ExhibitContentPage -->
<!-- ExhibitContentFooter Page -->
</HTML>
<!-- ExhibitContentFooter Page -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.06
<SEQUENCE>7
<FILENAME>exhibit6.htm
<DESCRIPTION>EX-99.06
<TEXT>
<!-- ExhibitContentHeader Page -->
<HTML>
<HEAD>
<TITLE>
Exhibit&nbsp;&nbsp;EX-99.06
</TITLE>
</HEAD>
<!-- End HTML Header Page -->
<!-- ExhibitContentPage -->

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt">March&nbsp;5, 2008
</FONT>

<P align="left" style="font-size: 12pt">PHILIPS AND RESPIRONICS ANNOUNCE SATISFACTION OF ANTITRUST APPROVALS CONDITION TO TENDER OFFER


<P align="left" style="font-size: 12pt">Amsterdam, The Netherlands and Murrysville, Pennsylvania, USA&#151;Royal Philips Electronics (NYSE:PHG,
AEX:PHI) (&#147;Philips&#148;) and Respironics, Inc. (NASDAQ:RESP) (&#147;Respironics&#148;) today announced that
approval under Council Regulation (EC)&nbsp;No.&nbsp;139/2004 of the European Community, as amended, was
obtained today, which approval is a condition to the tender offer by Philips&#146; wholly owned
subsidiary, Moonlight Merger Sub, Inc., to acquire all outstanding shares of common stock of
Respironics for $66.00 per Respironics share, without interest and subject to any applicable
withholding of taxes. Accordingly, the antitrust approvals condition to the tender offer has been
fully satisfied. The tender offer is currently scheduled to expire at 5:00 p.m., New York City
time, on Thursday, March&nbsp;6, 2008.


<P align="left" style="font-size: 12pt">Investors and stockholders of Respironics are urged to read the Tender Offer Statement on Schedule
TO (containing the offer to purchase, a letter of transmittal and related materials) relating to
the tender offer that has been filed with the Securities and Exchange Commission (the &#147;SEC&#148;)
because it contains important information, including the various terms of, and conditions to, the
tender offer. Investors and stockholders of Respironics may obtain these and other documents
regarding the tender offer, the merger and the related transactions filed by Moonlight Merger Sub,
Inc. and Respironics for free from the SEC&#146;s website at www.sec.gov.


<P align="left" style="font-size: 12pt">Georgeson Inc. is the Information Agent for the tender offer and any questions or requests for
assistance or free copies of the offer to purchase and the letter of transmittal may be directed to
it at 199 Water Street, 26th Floor, New York, NY 10038 or by telephone toll-free at (800)&nbsp;491-3017
or at (212)&nbsp;440-9800 (bankers and brokers only). Deutsche Bank is the Dealer Manager for the tender
offer and can be reached at 60 Wall Street, New York, NY 10005 or by telephone toll-free at (877)
221-7676.


<P align="left" style="font-size: 12pt">This release is for informational purposes only and is not an offer to purchase or a solicitation
of an offer to sell Respironics shares, nor is it an offer to purchase or a solicitation of an
offer to sell any securities. The tender offer is made solely by means of the offer to purchase.


<P align="left" style="font-size: 12pt">For further information, please contact:
<BR>
Arent Jan Hesselink
<BR>
Philips Corporate Communications
<BR>
Tel: &#043;31 20 59 77415
<BR>
Email: arentjan.hesselink@philips.com


<P align="left" style="font-size: 12pt">Andre Manning
<BR>
Philips Healthcare
<BR>
Tel: &#043;1 646 508 4545
<BR>
Email: andre.manning@philips.com


<P align="left" style="font-size: 12pt">Dan Bevevino
<BR>
Vice President &#038; CFO, Respironics
<BR>
Tel: &#043;1 724 387 5235


<P align="left" style="font-size: 12pt">Maryellen Bizzack
<BR>
Director, Marketing &#038; Communications, Respironics
<BR>
Tel: &#043;1 724 387 5006


<P align="left" style="font-size: 12pt">About Royal Philips Electronics
<BR>
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in
healthcare, lighting and consumer lifestyle, delivering people-centric, innovative products,
services and solutions through the brand promise of &#147;sense and simplicity&#148;. Headquartered in the
Netherlands, Philips employs approximately 123,800 employees in more than 60 countries worldwide.
With sales of EUR 27&nbsp;billion in 2007, the company is a market leader in medical diagnostic imaging
and patient monitoring systems, energy efficient lighting solutions, as well as lifestyle solutions
for personal wellbeing. News from Philips is located at www.philips.com/newscenter.


<P align="left" style="font-size: 12pt">About Respironics
<BR>
Respironics is a leading developer, manufacturer and distributor of innovative products and
programs that serve the global sleep and respiratory markets. Focusing on emerging market needs,
Respironics is committed to providing valued solutions to help improve outcomes for patients,
clinicians and healthcare providers. Respironics markets its products in 141 countries and employs
over 5,300 associates worldwide. Further information can be found on Respironics&#146; Web site:
www.respironics.com.


<P align="left" style="font-size: 12pt">Forward-looking statements
<BR>
This release may contain certain forward-looking statements with respect to the financial
condition, results of operations and business of Philips and certain of the plans and objectives of
Philips with respect to these items, including without limitation completion of the tender offer
and merger and any expected benefits of the merger. Completion of the tender offer and merger are
subject to conditions, including satisfaction of a minimum tender condition, and there can be no
assurance that those conditions can be satisfied or that the transactions described in this press
release will completed. By their nature, forward-looking statements involve risk and uncertainty
because they relate to events and depend on circumstances that will occur in the future and there
are many factors that could cause actual results and developments to differ materially from those
expressed or implied by these forward-looking statements. Any forward-looking statements in this
announcement are based upon information known to Philips on the date of this announcement. Philips
undertakes no obligation to publicly update or revise any forward-looking statement, whether as a
result of new information, future events or otherwise.



<P align="center" style="font-size: 10pt; display: none">


<!-- v.060107 -->
</BODY>

<!-- End ExhibitContentPage -->
<!-- ExhibitContentFooter Page -->
</HTML>
<!-- ExhibitContentFooter Page -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.07
<SEQUENCE>8
<FILENAME>exhibit7.htm
<DESCRIPTION>EX-99.07
<TEXT>
<!-- ExhibitContentHeader Page -->
<HTML>
<HEAD>
<TITLE>
Exhibit&nbsp;&nbsp;EX-99.07
</TITLE>
</HEAD>
<!-- End HTML Header Page -->
<!-- ExhibitContentPage -->

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt">March&nbsp;5, 2008
</FONT>

<P align="left" style="font-size: 12pt">MR.&nbsp;LOUIS SCHWEITZER TO STEP DOWN FROM SUPERVISORY BOARD OF ROYAL PHILIPS ELECTRONICS


<P align="left" style="font-size: 12pt">Amsterdam, The Netherlands &#150; Royal Philips Electronics (AEX: PHI, NYSE: PHG) today announced that
Mr.&nbsp;Louis Schweitzer, Vice Chairman and Secretary to Philips&#146; Supervisory Board, will step down
from Philips&#146; Supervisory Board effective upon the closing of Philips&#146; 2008 Annual General Meeting
of Shareholders, to be held March&nbsp;27, 2008. Mr.&nbsp;Schweitzer expressed his wish to relinquish this
position in view of his announced appointment as chairman of the supervisory board of the French
newspaper group Le Monde.


<P align="left" style="font-size: 12pt">&#147;I would like to express my sincere gratitude to Mr.&nbsp;Schweitzer, who has been an active member of
Philips&#146; Supervisory Board for more than 10&nbsp;years,&#148; said Philips&#146; Chairman of the Supervisory
Board, Mr.&nbsp;Wim de Kleuver. &#147;During close to three full terms on Philips&#146; Supervisory Board, Mr.
Schweitzer provided very valuable guidance and counsel to Philips during a significant period of
transition at the company.&#148;


<P align="left" style="font-size: 12pt">A former CEO of Renault and Renault-Nissan BV and current chairman of the board of Renault and
AstraZenea, Mr.&nbsp;Schweitzer first joined Philips&#146; Supervisory Board in 1997 and became Vice-Chairman
and Secretary Member of the Supervisory Board in 2005.


<P align="left" style="font-size: 12pt">Additional information on the composition of the Supervisory Board and on Philips&#146; full-year
results, which were first presented January&nbsp;21, 2008, is included in Philips&#146; 2007 Annual Report.
<BR>
Click <U>here</U> to view the Annual Report 2007.


<P align="left" style="font-size: 12pt">For more information, please contact:
<BR>
Jayson Otke
<BR>
Philips Corporate Communications:
<BR>
Tel: &#043;31 20 59 77215
<BR>
Email: jayson.otke@philips.com


<P align="left" style="font-size: 12pt">About Royal Philips Electronics
<BR>
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in
healthcare, lighting and consumer lifestyle, delivering people-centric, innovative products,
services and solutions through the brand promise of &#147;sense and simplicity&#148;. Headquartered in the
Netherlands, Philips employs approximately 123,800 employees in more than 60 countries worldwide.
With sales of EUR 27&nbsp;billion in 2007, the company is a market leader in medical diagnostic imaging
and patient monitoring systems, energy efficient lighting solutions, as well as lifestyle solutions
for personal wellbeing. News from Philips is located at www.philips.com/newscenter.


<P align="left" style="font-size: 12pt">Forward-looking statements
<BR>
This release may contain certain forward-looking statements with respect to the financial
condition, results of operations and business of Philips and certain of the plans and objectives of
Philips with respect to these items. By their nature, forward-looking statements involve risk and
uncertainty because they relate to events and depend on circumstances that will occur in the future
and there are many factors that could cause actual results and developments to differ materially
from those expressed or implied by these forward-looking statements.



<P align="center" style="font-size: 10pt; display: none">


<!-- v.060107 -->
</BODY>

<!-- End ExhibitContentPage -->
<!-- ExhibitContentFooter Page -->
</HTML>
<!-- ExhibitContentFooter Page -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.08
<SEQUENCE>9
<FILENAME>exhibit8.htm
<DESCRIPTION>EX-99.08
<TEXT>
<!-- ExhibitContentHeader Page -->
<HTML>
<HEAD>
<TITLE>
Exhibit&nbsp;&nbsp;EX-99.08
</TITLE>
</HEAD>
<!-- End HTML Header Page -->
<!-- ExhibitContentPage -->

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt">March&nbsp;6, 2008
</FONT>

<P align="left" style="font-size: 12pt">PHILIPS SUCCESSFULLY PLACES USD 3.1 BILLION WORTH OF SENIOR NOTES


<P align="left" style="font-size: 12pt">Amsterdam, The Netherlands <B>&#150; </B>Royal Philips Electronics (NYSE:PHG, AEX:PHI) today announced that it
has placed a total of USD 3.1&nbsp;billion worth of new Philips Senior Notes as part of its previously
announced USD benchmark issue. Philips intends to use the proceeds of this offering to refinance
the EUR 1.7&nbsp;billion worth of Philips notes that mature during the course of 2008, the majority of
which consists of the EUR 1.5&nbsp;billion 5.75% notes due May&nbsp;16, 2008, and for general corporate
purposes.


<P align="left" style="font-size: 12pt">Philips has placed a total of USD 350&nbsp;million worth of 3-month USD Libor &#043;1.15% Floating Rate Notes
due 2011, USD 500&nbsp;million worth of 4.625% Senior Notes due 2013, USD 1.25&nbsp;billion worth of 5.750%
Senior Notes due 2018 and USD 1.0&nbsp;billion worth of 6.875% Senior Notes due 2038.


<P align="left" style="font-size: 12pt">Philips&#146; existing long-term debt is rated A3 stable outlook by Moody&#146;s and A- stable outlook by
Standard &#038; Poor&#146;s. The issuance of these Notes is in line with Philips&#146; objective to maintain
current credit ratings.


<P align="left" style="font-size: 12pt">For more information, please contact:
<BR>
Arent Jan Hesselink
<BR>
Philips Corporate Communications
<BR>
Tel: &#043;31 20 59 77415
<BR>
Email: arentjan.hesselink@philips.com


<P align="left" style="font-size: 12pt">About Royal Philips Electronics
<BR>
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in
healthcare, lighting and consumer lifestyle, delivering people-centric, innovative products,
services and solutions through the brand promise of &#147;sense and simplicity&#148;. Headquartered in the
Netherlands, Philips employs approximately 123,800 employees in more than 60 countries worldwide.
With sales of EUR 27&nbsp;billion in 2007, the company is a market leader in medical diagnostic imaging
and patient monitoring systems, energy efficient lighting solutions, as well as lifestyle solutions
for personal wellbeing. News from Philips is located at www.philips.com/newscenter.


<P align="left" style="font-size: 12pt">Securities Ratings: The securities ratings referred to above in this release are not a
recommendation to buy, sell or hold securities and the ratings are subject to revision or
withdrawal at anytime by the assigning rating agencies. Each rating should be evaluated
independently of any other rating.


<P align="left" style="font-size: 12pt">This release does not constitute an offer of any securities for sale. Any offer or sale of
securities shall only be made in accordance with the requirements of the US Securities Act of 1933.
<BR>
Any offer and sale of any securities outside the United States will be made in accordance with
local laws and regulations. In addition, any offer of securities in the member states of the
European Economic Area shall be made to qualified investors only within the meaning of article 3 of
Directive 2003/71/EC (the Prospectus Directive).


<P align="left" style="font-size: 12pt">When available, a copy of the written prospectus can be obtained from J.P. Morgan Securities Inc,
270 Park Avenue New York, NY 10017, Attn: Nicholas Balzano (&#043;1-212-834-4533), or Citigroup Global
Markets, 33 Canada Square Canary Wharf London E14 5LB, Attn: Tomas Lundquist (&#043;44 20 7986 8962).



<P align="center" style="font-size: 10pt; display: none">


<!-- v.060107 -->
</BODY>

<!-- End ExhibitContentPage -->
<!-- ExhibitContentFooter Page -->
</HTML>
<!-- ExhibitContentFooter Page -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.09
<SEQUENCE>10
<FILENAME>exhibit9.htm
<DESCRIPTION>EX-99.09
<TEXT>
<!-- ExhibitContentHeader Page -->
<HTML>
<HEAD>
<TITLE>
Exhibit&nbsp;&nbsp;EX-99.09
</TITLE>
</HEAD>
<!-- End HTML Header Page -->
<!-- ExhibitContentPage -->

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt">March&nbsp;7, 2008
</FONT>

<P align="left" style="font-size: 12pt">PHILIPS ANNOUNCES CONDITIONS TO TENDER OFFER TO ACQUIRE RESPIRONICS HAVE BEEN MET


<P align="left" style="font-size: 12pt">Amsterdam, The Netherlands &#151; Royal Philips Electronics (NYSE:PHG, AEX:PHI) (&#147;Philips&#148;) today
announced all conditions to the closing of the tender offer by its wholly owned subsidiary,
Moonlight Merger Sub, Inc. (&#147;Philips Merger Sub&#148;), to acquire all outstanding shares of common
stock of Respironics, Inc. (NASDAQ:RESP) (&#147;Respironics&#148;) for $66.00 per Respironics share, without
interest and subject to any applicable withholding of taxes, have been met. One of the remaining
conditions for the closing of the tender offer included receiving more than 50% of the total number
of outstanding shares tendered into the offer. As of the expiration of the tender offer, at 5:00
p.m., New York City time, on March&nbsp;6, 2008, Philips Merger Sub had received approximately 69.1
million Respironics shares tendered into the offer, including approximately 4.4&nbsp;million Respironics
shares tendered by guaranteed delivery, together representing approximately 92.9% of the
outstanding shares of Respironics.


<P align="left" style="font-size: 12pt">Philips expects to promptly pay for all shares that were tendered on or prior to the expiration of
the offer.


<P align="left" style="font-size: 12pt">Philips also announced today that Philips Merger Sub has elected to provide a subsequent offering
period of 5 business days, which commences today and will expire at 5:00 p.m., New York City time,
on March&nbsp;13, 2008. Holders of Respironics shares who have not already tendered their shares may do
so at any time before the expiration of the subsequent offering period. All Respironics shares
validly tendered during the subsequent offering period will be immediately accepted and payment of
$66.00 per Respironics share, without interest and subject to any applicable withholding of taxes,
will be made promptly after acceptance in accordance with the terms of the offer. This amount is
the same consideration that Philips Merger Sub will pay for Respironics shares tendered into the
initial offering period, as extended, which expired on March&nbsp;6, 2008. No shares tendered into the
subsequent offering period may be withdrawn after having been tendered. The purpose of the
subsequent offering period is to enable holders of Respironics shares who did not tender their
shares prior to the expiration of the initial offering period to participate in the offer and
receive, on an expedited basis, $66.00 per Respironics share, without interest and subject to any
applicable withholding of taxes.


<P align="left" style="font-size: 12pt">Investors and stockholders of Respironics are urged to read the Tender Offer Statement on Schedule
TO (containing the offer to purchase, a letter of transmittal and related materials) relating to
the tender offer that has been filed with the Securities and Exchange Commission (the &#147;SEC&#148;)
because it contains important information, including the various terms of, and conditions to, the
tender offer. Investors and stockholders of Respironics may obtain these and other documents
regarding the tender offer, the merger and the related transactions filed by Philips Merger Sub and
Respironics for free from the SEC&#146;s website at www.sec.gov.


<P align="left" style="font-size: 12pt">Georgeson Inc. is the Information Agent for the tender offer and any questions or requests for
assistance or free copies of the offer to purchase and the letter of transmittal may be directed to
it at 199 Water Street, 26th Floor, New York, NY 10038 or by telephone toll-free at (800)&nbsp;491-3017
or at (212)&nbsp;440-9800 (bankers and brokers only). Deutsche Bank is the Dealer Manager for the tender
offer and can be reached at 60 Wall Street, New York, NY 10005 or by telephone toll-free at (877)
221-7676.


<P align="left" style="font-size: 12pt">This release is for informational purposes only and is not an offer to purchase or a solicitation
of an offer to sell Respironics shares, nor is it an offer to purchase or a solicitation of an
offer to sell any securities. The tender offer is made solely by means of the offer to purchase.


<P align="left" style="font-size: 12pt">For further information, please contact:
<BR>
Arent Jan Hesselink
<BR>
Philips Corporate Communications
<BR>
Tel: &#043;31 20 59 77415
<BR>
Email: arentjan.hesselink@philips.com


<P align="left" style="font-size: 12pt">Andre Manning
<BR>
Philips Healthcare
<BR>
Tel: &#043;1 646 508 4545
<BR>
Email: andre.manning@philips.com


<P align="left" style="font-size: 12pt">Dan Bevevino
<BR>
Vice President &#038; CFO, Respironics
<BR>
Tel: &#043;1 724 387 5235


<P align="left" style="font-size: 12pt">Maryellen Bizzack
<BR>
Director, Marketing &#038; Communications, Respironics
<BR>
Tel: &#043;1 724 387 5006


<P align="left" style="font-size: 12pt">About Royal Philips Electronics
<BR>
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in
healthcare, lighting and consumer lifestyle, delivering people-centric, innovative products,
services and solutions through the brand promise of &#147;sense and simplicity&#148;. Headquartered in the
Netherlands, Philips employs approximately 123,800 employees in more than 60 countries worldwide.
With sales of EUR 27&nbsp;billion in 2007, the company is a market leader in medical diagnostic imaging
and patient monitoring systems, energy efficient lighting solutions, as well as lifestyle solutions
for personal wellbeing. News from Philips is located at www.philips.com/newscenter.


<P align="left" style="font-size: 12pt">About Respironics
<BR>
Respironics is a leading developer, manufacturer and distributor of innovative products and
programs that serve the global sleep and respiratory markets. Focusing on emerging market needs,
Respironics is committed to providing valued solutions to help improve outcomes for patients,
clinicians and healthcare providers. Respironics markets its products in 141 countries and employs
over 5,300 associates worldwide. Further information can be found on Respironics&#146; Web site:
www.respironics.com.


<P align="left" style="font-size: 12pt">Forward-looking statements
<BR>
This release may contain certain forward-looking statements with respect to the financial
condition, results of operations and business of Philips and certain of the plans and objectives of
Philips with respect to these items, including without limitation completion of the merger and any
expected benefits of the merger. Completion of the merger is subject to conditions, and there can
be no assurance that those conditions can be satisfied or that the transactions described in this
press release will completed. By their nature, forward-looking statements involve risk and
uncertainty because they relate to events and depend on circumstances that will occur in the future
and there are many factors that could cause actual results and developments to differ materially
from those expressed or implied by these forward-looking statements. Any forward-looking statements
in this announcement are based upon information known to Philips on the date of this announcement.
Philips undertakes no obligation to publicly update or revise any forward-looking statement,
whether as a result of new information, future events or otherwise.



<P align="center" style="font-size: 10pt; display: none">


<!-- v.060107 -->
</BODY>

<!-- End ExhibitContentPage -->
<!-- ExhibitContentFooter Page -->
</HTML>
<!-- ExhibitContentFooter Page -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.10
<SEQUENCE>11
<FILENAME>exhibit10.htm
<DESCRIPTION>EX-99.10
<TEXT>
<!-- ExhibitContentHeader Page -->
<HTML>
<HEAD>
<TITLE>
Exhibit&nbsp;&nbsp;EX-99.10
</TITLE>
</HEAD>
<!-- End HTML Header Page -->
<!-- ExhibitContentPage -->

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt">March&nbsp;12, 2008
</FONT>

<P align="left" style="font-size: 12pt">PHILIPS FURTHER LOWERS ITS STAKE IN LG DISPLAY TO 13.2%


<P align="left" style="font-size: 12pt">Amsterdam, The Netherlands &#150; Royal Philips Electronics (AEX: PHI, NYSE: PHG) today announced it has
sold 24&nbsp;million shares of common stock in LG Display Co., Ltd. (NYSE: LPL, KRX: 034220) to
investors in a capital markets transaction. This transaction represents 6.7% of LG Display&#146;s issued
share capital and reduces Philips&#146; holding to 13.2%.


<P align="left" style="font-size: 12pt">The transaction, which closed today, will provide Philips with net proceeds of approximately EUR
680&nbsp;million, and is expected to result in a non-taxable gain of approximately EUR 95&nbsp;million in the
first quarter of 2008, which will be recognized in financial income and expenses.


<P align="left" style="font-size: 12pt">This transaction is in line with Philips&#146; communicated strategy to further reduce its holding in LG
Display in a structured and responsible manner.


<P align="left" style="font-size: 12pt">For further information, please contact:
<BR>
Joon Knapen
<BR>
Philips Corporate Communications
<BR>
Tel. &#043;31 20 59 77 477
<BR>
Email: joon.knapen@philips.com


<P align="left" style="font-size: 12pt">About Royal Philips Electronics
<BR>
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in
healthcare, lighting and consumer lifestyle, delivering people-centric, innovative products,
services and solutions through the brand promise of &#147;sense and simplicity&#148;. Headquartered in the
Netherlands, Philips employs approximately 123,800 employees in more than 60 countries worldwide.
With sales of EUR 27&nbsp;billion in 2007, the company is a market leader in medical diagnostic imaging
and patient monitoring systems, energy efficient lighting solutions, as well as lifestyle solutions
for personal wellbeing. News from Philips is located at www.philips.com/newscenter.


<P align="left" style="font-size: 12pt">The offer and sale of securities referred to in this press release have not been, and will not be,
registered under the Securities Act of 1933, as amended (the &#147;Act&#148;), or under any other applicable
securities laws. They may not be sold, transferred, offered for sale, pledged, or hypothecated or
otherwise disposed of unless registered under the Act or pursuant to an exemption from the
registration requirements of the Act. This press release shall not constitute an offer to sell or
the solicitation of an offer to buy nor shall there be any sale of these securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such jurisdiction.



<P align="center" style="font-size: 10pt; display: none">


<!-- v.060107 -->
</BODY>

<!-- End ExhibitContentPage -->
<!-- ExhibitContentFooter Page -->
</HTML>
<!-- ExhibitContentFooter Page -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.11
<SEQUENCE>12
<FILENAME>exhibit11.htm
<DESCRIPTION>EX-99.11
<TEXT>
<!-- ExhibitContentHeader Page -->
<HTML>
<HEAD>
<TITLE>
Exhibit&nbsp;&nbsp;EX-99.11
</TITLE>
</HEAD>
<!-- End HTML Header Page -->
<!-- ExhibitContentPage -->

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt">March&nbsp;14, 2008
</FONT>

<P align="left" style="font-size: 12pt">PHILIPS ANNOUNCES COMPLETION OF TENDER OFFER TO ACQUIRE RESPIRONICS


<P align="left" style="font-size: 12pt">Amsterdam, The Netherlands&#151;Royal Philips Electronics (NYSE:PHG, AEX:PHI) (&#147;Philips&#148;) today
announced the completion of the tender offer by its wholly owned subsidiary, Moonlight Merger Sub,
Inc. (&#147;Philips Merger Sub&#148;), to acquire all outstanding shares of common stock of Respironics, Inc.
(NASDAQ:RESP) (&#147;Respironics&#148;) for $66.00 per Respironics share, without interest and subject to any
applicable withholding of taxes. As of the expiration of the previously announced subsequent
offering period for the tender offer, at 5:00 p.m., New York City time, on March&nbsp;13, 2008, Philips
Merger Sub had received over 70&nbsp;million Respironics shares tendered into the offer, representing
over 94% of the outstanding shares of Respironics. All Respironics shares validly tendered and not
withdrawn have been accepted for payment and the consideration for all such shares either has been
paid or will promptly be paid.


<P align="left" style="font-size: 12pt">Commenting on today&#146;s announcement, Gerard Kleisterlee, President and Chief Executive Officer of
Royal Philips Electronics, said: &#147;For Philips, the acquisition of Respironics will be a major
milestone towards completing our objective to build market leadership positions in high-growth,
high-margin markets around our three sectors. Upon closing of this transaction, Respironics will
become the centerpiece of our Home Healthcare business within Philips Healthcare and with that we
have successfully built a significant operation that can facilitate the evident societal need to
make home-based healthcare an integral part of the healthcare system.&#148;


<P align="left" style="font-size: 12pt">As the final step of the acquisition process, Philips intends to effect a short-form merger of
Philips Merger Sub with and into Respironics. Following the merger, Respironics will become an
indirect wholly owned subsidiary of Philips, and Respironics shares will be delisted and will cease
to trade on the NASDAQ National Market.


<P align="left" style="font-size: 12pt">Investors and stockholders of Respironics are urged to read the Tender Offer Statement on Schedule
TO (containing the offer to purchase, a letter of transmittal and related materials) relating to
the tender offer that has been filed with the Securities and Exchange Commission (the &#147;SEC&#148;)
because it contains important information, including the various terms of, and conditions to, the
tender offer. Investors and stockholders of Respironics may obtain these and other documents
regarding the tender offer, the merger and the related transactions filed by Philips Merger Sub and
Respironics for free from the SEC&#146;s website at www.sec.gov.
<BR>
This release is for informational purposes only and is not an offer to purchase or a solicitation
of an offer to sell Respironics shares, nor is it an offer to purchase or a solicitation of an
offer to sell any securities. The tender offer is made solely by means of the offer to purchase.


<P align="left" style="font-size: 12pt">For further information, please contact:
<BR>
Joon Knapen
<BR>
Philips Corporate Communications
<BR>
Tel: &#043;31 20 59 77477
<BR>
Email: joon.knapen@philips.com


<P align="left" style="font-size: 12pt">Andre Manning
<BR>
Philips Healthcare
<BR>
Tel: &#043;1 646 508 4545
<BR>
Email: andre.manning@philips.com


<P align="left" style="font-size: 12pt">Dan Bevevino
<BR>
Vice President &#038; CFO, Respironics
<BR>
Tel: &#043;1 724 387 5235


<P align="left" style="font-size: 12pt">Maryellen Bizzack
<BR>
Director, Marketing &#038; Communications, Respironics
<BR>
Tel: &#043;1 724 387 5006


<P align="left" style="font-size: 12pt">About Royal Philips Electronics
<BR>
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in
healthcare, lighting and consumer lifestyle, delivering people-centric, innovative products,
services and solutions through the brand promise of &#147;sense and simplicity&#148;. Headquartered in the
Netherlands, Philips employs approximately 123,800 employees in more than 60 countries worldwide.
With sales of EUR 27&nbsp;billion in 2007, the company is a market leader in medical diagnostic imaging
and patient monitoring systems, energy efficient lighting solutions, as well as lifestyle solutions
for personal wellbeing. News from Philips is located at www.philips.com/newscenter.


<P align="left" style="font-size: 12pt">About Respironics
<BR>
Respironics is a leading developer, manufacturer and distributor of innovative products and
programs that serve the global sleep and respiratory markets. Focusing on emerging market needs,
Respironics is committed to providing valued solutions to help improve outcomes for patients,
clinicians and healthcare providers. Respironics markets its products in 141 countries and employs
over 5,300 associates worldwide. Further information can be found on Respironics&#146; Web site:
www.respironics.com.


<P align="left" style="font-size: 12pt">Forward-looking statements
<BR>
This release may contain certain forward-looking statements with respect to the financial
condition, results of operations and business of Philips and certain of the plans and objectives of
Philips with respect to these items, including without limitation completion of the merger and any
expected benefits of the merger. Completion of the merger is subject to conditions, and there can
be no assurance that those conditions can be satisfied or that the transactions described in this
press release will completed. By their nature, forward-looking statements involve risk and
uncertainty because they relate to events and depend on circumstances that will occur in the future
and there are many factors that could cause actual results and developments to differ materially
from those expressed or implied by these forward-looking statements. Any forward-looking statements
in this announcement are based upon information known to Philips on the date of this announcement.
Philips undertakes no obligation to publicly update or revise any forward-looking statement,
whether as a result of new information, future events or otherwise.



<P align="center" style="font-size: 10pt; display: none">


<!-- v.060107 -->
</BODY>

<!-- End ExhibitContentPage -->
<!-- ExhibitContentFooter Page -->
</HTML>
<!-- ExhibitContentFooter Page -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.12
<SEQUENCE>13
<FILENAME>exhibit12.htm
<DESCRIPTION>EX-99.12
<TEXT>
<!-- ExhibitContentHeader Page -->
<HTML>
<HEAD>
<TITLE>
Exhibit&nbsp;&nbsp;EX-99.12
</TITLE>
</HEAD>
<!-- End HTML Header Page -->
<!-- ExhibitContentPage -->

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt">March&nbsp;17, 2008
</FONT>

<P align="left" style="font-size: 12pt">PHILIPS ANNOUNCES COMPLETION OF RESPIRONICS ACQUISITION


<P align="left" style="font-size: 12pt">Amsterdam, The Netherlands and Murrysville, Pennsylvania, USA &#151;Royal Philips Electronics (NYSE:PHG,
AEX:PHI) (&#147;Philips&#148;) and Respironics, Inc. (NASDAQ:RESP) (&#147;Respironics&#148;) today announced that
Philips has completed the acquisition of Respironics through the merger of its indirect wholly
owned subsidiary with and into Respironics. As a result of the merger, Respironics has become an
indirect wholly owned subsidiary of Philips.


<P align="left" style="font-size: 12pt">As of March&nbsp;10, 2008, Respironics&#146; financial results will be accounted for in the financial results
of Philips Healthcare.


<P align="left" style="font-size: 12pt">With the completion of the Respironics acquisition, Philips has rounded off an active period of
acquisitions in its Philips Healthcare sector. In addition to Respironics, Philips Healthcare has
also recently completed the acquisitions of clinical IT companies VISICU Inc. and Emergin, Inc. As
a result, Philips provisionally anticipates acquisition and integration charges related to the
Respironics, Visicu and Emergin acquisitions of approximately EUR&nbsp;200&nbsp;million for 2008, of which
approximately EUR&nbsp;100&nbsp;million is expected to impact Philips&#146; 2008 EBITA. Philips expects to book
approximately EUR&nbsp;40&nbsp;million of the acquisition and integration charges in the first quarter of
2008, of which approximately EUR&nbsp;25&nbsp;million will impact Philips&#146; first quarter 2008 EBITA.


<P align="left" style="font-size: 12pt">Respironics has requested that NASDAQ file a Form&nbsp;25 with the United States Securities and Exchange
Commission causing the delisting of Respironics&#146; common stock from NASDAQ and the deregistration of
its common stock under the United States federal securities laws.


<P align="left" style="font-size: 12pt">For further information, please contact:
<BR>
Joon Knapen
<BR>
Philips Corporate Communications
<BR>
Tel: &#043;31 20 59 77477
<BR>
Email: joon.knapen@philips.com


<P align="left" style="font-size: 12pt">Andre Manning
<BR>
Philips Healthcare
<BR>
Tel: &#043;1 646 508 4545
<BR>
Email: andre.manning@philips.com


<P align="left" style="font-size: 12pt">Dan Bevevino
<BR>
Vice President &#038; CFO, Respironics
<BR>
Tel: &#043;1 724 387 5235


<P align="left" style="font-size: 12pt">Maryellen Bizzack
<BR>
Director, Marketing &#038; Communications, Respironics
<BR>
Tel: &#043;1 724 387 5006


<P align="left" style="font-size: 12pt">About Royal Philips Electronics
<BR>
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in
healthcare, lighting and consumer lifestyle, delivering people-centric, innovative products,
services and solutions through the brand promise of &#147;sense and simplicity&#148;. Headquartered in the
Netherlands, Philips employs approximately 123,800 employees in more than 60 countries worldwide.
With sales of EUR 27&nbsp;billion in 2007, the company is a market leader in medical diagnostic imaging
and patient monitoring systems, energy efficient lighting solutions, as well as lifestyle solutions
for personal wellbeing. News from Philips is located at www.philips.com/newscenter.


<P align="left" style="font-size: 12pt">About Respironics
<BR>
Respironics is a leading developer, manufacturer and distributor of innovative products and
programs that serve the global sleep and respiratory markets. Focusing on emerging market needs,
Respironics is committed to providing valued solutions to help improve outcomes for patients,
clinicians and healthcare providers. Respironics markets its products in 141 countries and employs
over 5,300 associates worldwide. Further information can be found on Respironics&#146; Web site:
www.respironics.com.


<P align="left" style="font-size: 12pt">Forward-looking statements
<BR>
This release may contain certain forward-looking statements with respect to the financial
condition, results of operations and business of Philips and certain of the plans and objectives of
Philips with respect to these items. By their nature, forward-looking statements involve risk and
uncertainty because they relate to events and depend on circumstances that will occur in the future
and there are many factors that could cause actual results and developments to differ materially
from those expressed or implied by these forward-looking statements. Any forward-looking statements
in this announcement are based upon information known to Philips on the date of this announcement.
Philips undertakes no obligation to publicly update or revise any forward-looking statement,
whether as a result of new information, future events or otherwise.



<P align="center" style="font-size: 10pt; display: none">


<!-- v.060107 -->
</BODY>

<!-- End ExhibitContentPage -->
<!-- ExhibitContentFooter Page -->
</HTML>
<!-- ExhibitContentFooter Page -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.13
<SEQUENCE>14
<FILENAME>exhibit13.htm
<DESCRIPTION>EX-99.13
<TEXT>
<!-- ExhibitContentHeader Page -->
<HTML>
<HEAD>
<TITLE>
Exhibit&nbsp;&nbsp;EX-99.13
</TITLE>
</HEAD>
<!-- End HTML Header Page -->
<!-- ExhibitContentPage -->

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt">March&nbsp;19, 2008
</FONT>

<P align="left" style="font-size: 12pt">Philips and Ascent Profit sign <FONT face="'Times New Roman',times,serif">&#128;</FONT>25&nbsp;million contract to deliver digital radiography systems to China
in 2008


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 12pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Chinese hospitals take advantage of Philips&#146; advanced radiography solutions in effort to
provide improved care for millions of patients</TD>
</TR>

</TABLE>


<P align="left" style="font-size: 12pt">Shanghai, China &#150; Royal Philips Electronics (NYSE: PHG, AEX: PHI) and Ascent Profit, a leading
Chinese medical equipment wholesaler, today announced that they have signed a <FONT face="'Times New Roman',times,serif">&#128;</FONT>25&nbsp;million contract
to bring digital radiography systems to hospitals in China. This is the continuation of a similar
agreement made in 2007 and strengthens Philips&#146; position in the fast-growing Chinese healthcare
market. It will enable hospitals across the country to benefit from advanced imaging capabilities
and the efficiency of digital workflows.


<P align="left" style="font-size: 12pt">The productivity and cost benefits of digital radiography meet the needs of Chinese healthcare
facilities, enabling them to raise the quality of care while increasing the number of patients they
can treat. Digital X-ray systems are now being broadly implemented in the country&#146;s major
hospitals, making digital radiography one of the fastest-growing segments in the China&#146;s healthcare
market.


<P align="left" style="font-size: 12pt">Through the agreement with Ascent Profit, Chinese healthcare facilities have access to advanced
Philips digital radiography solutions, allowing them to take full advantage of the benefits that
digital radiology offers. These benefits include faster image information, time savings through
digital integration, and cost reduction through improved workflows and increased patient
throughput.


<P align="left" style="font-size: 12pt">&#147;This agreement with Ascent Profit will enable us to further expand our market coverage to the
second and third tier cities and less developed rural areas to meet the growing requirement for
rural and community healthcare,&#148; said David Jin, CEO of Philips Healthcare for Greater China. &#147;It
also exemplifies our continued effort to improve lives through solutions designed around the needs
of care providers and patients.&#148;


<P align="left" style="font-size: 12pt">&#147;Listening to our customers and understanding their needs is at the center of our business. Working
closely with our dealers and customers in China ensures that we can transform our customer insights
into the right solutions that exactly meet their needs. Our digital radiography solutions provide
highly advanced imaging capabilities and the efficiency of digital workflows &#150; improving care for
patients in China,&#148; said Christiaan Neeleman, general manager General X-ray at Philips Healthcare.


<P align="left" style="font-size: 12pt">&#147;Digital radiography is one of the fastest-growing segments in the Chinese healthcare market and we
are delighted to continue our relationship with Philips in 2008,&#148; commented Lin Yang Chen, general
manager of Ascent Profit. &#147;By working with Philips we can provide hospitals across the country with
a sophisticated digital radiography solution, offering a highly intuitive user interface and some
of the best quality images available in the market.&#148;


<P align="left" style="font-size: 12pt">For further information please contact:
<BR>
Europe/Middle East:
<BR>
Gert van Santen
<BR>
Director of Healthcare Communications EMEA
<BR>
Philips International
<BR>
Tel: &#043;31 612 969 748
<BR>
E-mail: Gert.van.Santen@philips.com


<P align="left" style="font-size: 12pt">USA:
<BR>
Steve Kelly
<BR>
Director, Public Relations, Corporate Communications
<BR>
Philips Healthcare
<BR>
Tel: &#043;1 (800)&nbsp;722-7900 ext. 7479
<BR>
Email: Steve.Kelly@philips.com

&nbsp;

<P align="left" style="font-size: 12pt"><B>About Royal Philips Electronics</B>
<BR>
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in
healthcare, lighting and consumer lifestyle, delivering people-centric, innovative products,
services and solutions through the brand promise of &#147;sense and simplicity&#148;. Headquartered in the
Netherlands, Philips employs approximately 123,800 employees in more than 60 countries worldwide.
With sales of EUR 27&nbsp;billion in 2007, the company is a market leader in medical diagnostic imaging
and patient monitoring systems, energy efficient lighting solutions, as well as lifestyle solutions
for personal wellbeing. News from Philips is located at <U>www.philips.com/newscenter</U>.



<P align="center" style="font-size: 10pt; display: none">


<!-- v.060107 -->
</BODY>

<!-- End ExhibitContentPage -->
<!-- ExhibitContentFooter Page -->
</HTML>
<!-- ExhibitContentFooter Page -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.14
<SEQUENCE>15
<FILENAME>exhibit14.htm
<DESCRIPTION>EX-99.14
<TEXT>
<!-- ExhibitContentHeader Page -->
<HTML>
<HEAD>
<TITLE>
Exhibit&nbsp;&nbsp;EX-99.14
</TITLE>
</HEAD>
<!-- End HTML Header Page -->
<!-- ExhibitContentPage -->

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt">March&nbsp;20, 2008
</FONT>

<P align="left" style="font-size: 12pt">PHILIPS COMPLETES CANCELLATION OF 59.9 MILLION SHARES


<P align="left" style="font-size: 12pt">Amsterdam, The Netherlands &#150; Royal Philips Electronics (NYSE:PHG, AEX:PHI) announced today that it
has completed the cancellation of in total 59,907,089 shares which have been acquired for
cancellation purposes during the period starting March&nbsp;7, 2007 up to and including March&nbsp;18, 2008
against an average repurchase price of EUR 28.64 per share. These shares have been repurchased
under the share repurchase program Philips had in place in 2007 and the EUR 5&nbsp;billion program the
company announced on December&nbsp;19, 2007 which is currently being executed.


<P align="left" style="font-size: 12pt">In connection with this share capital reduction, Philips has notified the Netherlands Authority for
the Financial Markets (AFM)&nbsp;that it no longer holds 5 per cent of its own shares. As a result of
the cancellation of shares, Philips&#146; issued share capital as per today amounts to 1,082,919,674
shares of which 51,535,354 shares are held by Philips to cover long-term incentive and employee
stock purchase plans.


<P align="left" style="font-size: 12pt">For more information, please contact:
<BR>
Arent Jan Hesselink
<BR>
Philips Corporate Communications:
<BR>
Tel: &#043;31 20 5977415
<BR>
Email: arentjan.hesselink@philips.com


<P align="left" style="font-size: 12pt">About Royal Philips Electronics
<BR>
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in
healthcare, lighting and consumer lifestyle, delivering people-centric, innovative products,
services and solutions through the brand promise of &#147;sense and simplicity&#148;. Headquartered in the
Netherlands, Philips employs approximately 123,800 employees in more than 60 countries worldwide.
With sales of EUR 27&nbsp;billion in 2007, the company is a market leader in medical diagnostic imaging
and patient monitoring systems, energy efficient lighting solutions, as well as lifestyle solutions
for personal wellbeing. News from Philips is located at www.philips.com/newscenter.


<P align="left" style="font-size: 12pt">Forward-looking statements
<BR>
This release may contain certain forward-looking statements with respect to the financial
condition, results of operations and business of Philips and certain of the plans and objectives of
Philips with respect to these items. By their nature, forward-looking statements involve risk and
uncertainty because they relate to events and depend on circumstances that will occur in the future
and there are many factors that could cause actual results and developments to differ materially
from those expressed or implied by these forward-looking statements.



<P align="center" style="font-size: 10pt; display: none">


<!-- v.060107 -->
</BODY>

<!-- End ExhibitContentPage -->
<!-- ExhibitContentFooter Page -->
</HTML>
<!-- ExhibitContentFooter Page -->
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
